iVigee published the Netherlands policy on risk minimization measures
Public source
Publisher name
Public post
If your team files in China or markets in the Netherlands, this week’s regulatory update is worth a quick look. China’s Chinese translation of ICH E2D(R1) is out for con…
Company
iVigee
- Industry
- Biotechnology Research
- Location
- Burlington, US
- Company size
- 51–200 employees
About iVigee
iVigee delivers physician-led pharmacovigilance grounded in truth. You receive pharmacovigilance services and consulting across the entire product lifecycle, from clinical development through post-marketing authorization. Our approach is built on transparency, regulatory realism, and straight answers you can trust, so you’re never left guessing. You work with physicians, former regulators, EU QPPVs, and senior safety leaders who understand how pharmacovigilance is evaluated in real inspections. We focus on what regulators actually look for, what they question, and what they expect you to explain, not just what guidance says. We support you as you build, optimize, and transform your pharmacovigilance capabilities, providing clarity at every stage, from early system design through mature, inspection-ready operations. Across everything we do, you always know where you stand, before inspections, before submissions, and before issues become findings. iVigee operates under an ISO 9001: 2015 – certified quality management system, ensuring the way we work is as structured, consistent, and accountable as the systems we help you establish and maintain.
See moreLatest activity
Latest activity from iVigee
13 signals
Presence & Recognition
iVigee hosted a conversation between Henry Seto and Jan Petracek discussing how AI is changing pharmacovigilance work and supervising it.
Presence & Recognition
iVigee hosted a conversation with Henry Seto discussing AI taking over daily pharmacovigilance work and supervising it.
Research & Knowledge
iVigee published the Chinese translation of ICH E2D(R1) for consultation in China
Discover more
Similar signals
Similar public activity from other companies.
Research & Knowledge
AzurBio
AzurBio notes that the European Medicines Agency launched an 18-month pilot of its revised Pre-Submission Interactions (PSI) model for initial Marketing Authorisation Applications (MAAs) under the centralised procedure in September 2026.
Research & Knowledge
GeneGoCell Inc.
GeneGoCell Inc. published an April 2026 draft guidance on the Safety Assessment of Genome Editing in Human Gene Therapy Products Using NGS.
Research & Knowledge
European Medicines Agency
European Medicines Agency published a guest article authored by Evdokia Korakianiti, the Head of Quality and Safety Department, discussing a pilot that allows regulators to review company submissions simultaneously when important manufacturing changes are made after a medicine was approved.
Research & Knowledge
Health Holland
Health Holland published a new Insight by Strategie Manager Marquerite Sallons exploring the transition from care to health and how health innovation can contribute to a system that is both more efficient and more patient-friendly.
Research & Knowledge
Kiin Bio